Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2016; 22(5): 1736-1744
Published online Feb 7, 2016. doi: 10.3748/wjg.v22.i5.1736
Clinical and molecular features of young-onset colorectal cancer
Veroushka Ballester, Shahrooz Rashtak, Lisa Boardman
Veroushka Ballester, Shahrooz Rashtak, Lisa Boardman, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, United States
Author contributions: Ballester V and Rashtak S performed the analytic review of the literature; Ballester V, Rashtak S and Boardman L wrote the paper.
Conflict-of-interest statement: The authors have no conflicts of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Lisa Boardman, MD, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States.
Telephone: +1-507-2664338 Fax: +1-507-2660350
Received: July 9, 2015
Peer-review started: July 9, 2015
First decision: September 29, 2015
Revised: October 25, 2015
Accepted: December 14, 2015
Article in press: December 14, 2015
Published online: February 7, 2016


Colorectal cancer (CRC) is one of the leading causes of cancer related mortality worldwide. Although young-onset CRC raises the possibility of a hereditary component, hereditary CRC syndromes only explain a minority of young-onset CRC cases. There is evidence to suggest that young-onset CRC have a different molecular profile than late-onset CRC. While the pathogenesis of young-onset CRC is well characterized in individuals with an inherited CRC syndrome, knowledge regarding the molecular features of sporadic young-onset CRC is limited. Understanding the molecular mechanisms of young-onset CRC can help us tailor specific screening and management strategies. While the incidence of late-onset CRC has been decreasing, mainly attributed to an increase in CRC screening, the incidence of young-onset CRC is increasing. Differences in the molecular biology of these tumors and low suspicion of CRC in young symptomatic individuals, may be possible explanations. Currently there is no evidence that supports that screening of average risk individuals less than 50 years of age will translate into early detection or increased survival. However, increasing understanding of the underlying molecular mechanisms of young-onset CRC could help us tailor specific screening and management strategies. The purpose of this review is to evaluate the current knowledge about young-onset CRC, its clinicopathologic features, and the newly recognized molecular alterations involved in tumor progression.

Key Words: Young-onset colorectal cancer, Late-onset colorectal cancer, Microsatellite instability, CpG island methylator phenotype, Chromosomal instability, Microsatellite, Chromosome stable colorectal cancer

Core tip: Recent evidence supports that young-onset colorectal cancer (CRC) is a “heterogeneous disease”. Newly recognized molecular alterations implicated in tumor progression, appear to contribute to its heterogeneity. Young-onset CRCs are remarkably different compared to late onset CRCs. These differences are highlighted by distinctive histologic features, site of tumor location, stage at presentation, and molecular profile. These differences support the possibility that young-onset CRC may be a different entity than late-onset CRCs. Understanding the molecular mechanisms underlying the development of young-onset CRC, will ultimately help individualize screening strategies and management for this high risk group.


Colorectal cancer (CRC) is the third most common cancer in the United States and is the second leading cause of cancer related mortality after lung cancer[1]. Young-onset CRC is an “heterogenous disease”, thought to have a strong hereditary component, although most cases are sporadic[2]. It accounts for 2% to 8% of all CRC. The incidence of CRC per 100000 young individuals, between the ages of 20-49 years, increased 1.5% per year in men and 1.6% per year in women from 1992 to 2005[3]. This contrasts with the incidence of late onset CRC, which has been decreasing, mainly attributed to an increase in CRC screening. A study by Chang et al[4] evaluated a cohort of 75 CRCs in patients younger than 40 years, and found that 22% of these tumors were due to hereditary cancer syndromes; 17% demonstrated abnormalities in the mismatch repair genes and 5% had germline genetic disorders predisposing to CRC. Different molecular alterations contribute to the “heterogeneity” of young-onset CRC and there is evidence to suggest that compared with late-onset CRC, young-onset CRC may have a different molecular profile[2] (Table 1). The increasing incidence of young onset CRC along with its aggressive nature, emphasize not only the importance of awareness of risk factors in this age group, but also the importance of early evaluation in young individuals with symptoms.

Table 1 Clinicopathologic and molecular differences between young-onset and late-onset colorectal cancer.
Clinical and molecular characteristicsYoung-onset CRC(50 yr)Late-onset CRC(> 50 yr)
Proximal colonX
Distal colon and rectumX
Synchronous and metachronous CRCX
Later stage at diagnosis (stage III/IV)X
Mucinous/signet ring and poorly differentiated featuresX
Typically MSSX
MSI due to MLH1 gene promoter methylationX
Microsatellite and chromosome stable CRCX
Hypomethylation of LINE 1X

Young-onset CRC is one of the “hallmarks” for Hereditary CRC Syndromes. Although young-onset CRC raises the possibility of an hereditary component, hereditary CRC syndromes represent 15%-20% of cases in this group[2,3]. Hereditary CRC syndromes only explain a minority of young-onset CRC cases, consequently, the pathogenic mechanisms in the majority of young onset CRC cases remains to be elucidated.

The purpose of this review is to evaluate the current knowledge about young-onset CRC, its clinicopathologic features, and the newly recognized molecular alterations involved in tumor progression.


We extensively searched the literature for English articles and abstracts from 1946 through March 2015 on MEDLINE, EMBASE, Web of Science, Scopus, and A combination of controlled vocabulary (MeSH, EMTREE) was used for MEDLINE and EMBASE. The terms “colorectal” or “colo rectal”, “cancer”, “adenocarcinoma”, “carcinoma, “early onset” or “young onset” was applied in the searching process. Subject headings and publication types, including “clinical trials”, “case reports”, “case series”, “controlled trials”, “randomized controlled trials”, “cohort studies”, “retrospective/prospective studies”, “major clinical studies”, “meta-analysis”, and “systematic review”, were used to identify the relevant literature. Cited articles were selected based on the novelty and the relevancy to the purpose of this review.


Studies have shown that individuals with young-onset CRC have distinctive histologic features, site of tumor location, and stage at presentation. Compared with late-onset CRC, young-onset CRC occur most often in the distal colon and the rectum (69.0% vs 57.7%, P < 0.001)[5]. A study by Davis et al[6], which included data from the SEER Program of the National Cancer Institute, showed that in the 35 to 39 age group, 32% of tumors occurred in the rectum. This gradually decreased in subsequent age groups to a low of 15.1% in the 85 years and older age group[6]. The opposite trend was seen for cancers located in the cecum. In the 35 to 39 age group, 9.3% of the tumors occurred in the cecum. This increased in subsequent age groups to a high of 23.2% in the 85 years and older age group[6]. Young-onset CRC is also associated with a higher percentage of synchronous and metachronous tumors. A study by Liang et al[7], which evaluated the clinicopathological and molecular characteristics of young-onset CRC, showed a higher incidence of synchronous (5.8% vs 1.2%, P = 0.007) and metachronous (4.0% vs 1.6%, P = 0.023) cancers in young individuals (younger than 40 years), when compared to older individuals.

Mucinous and signet ring features, as well as poorly differentiated histology, are typically associated with young-onset CRC. Data from the National Cancer Database showed that compared with later-onset CRC, young-onset CRC more frequently exhibited a mucinous and signet-ring histology (12.6% vs 10.8%, P < 0.001) and poor or no differentiation (20.4% vs 18%; P < 0.001)[8]. The reason for these histological differences is unknown, but differences in the molecular biology of these tumors may be a possible explanation[8]. Advanced-stage disease was more commonly diagnosed in young patients[5]. Later stage at diagnosis, could be related to lower screening rates and/or failure to recognize and evaluate symptoms in young individuals[8]. Data from the SEER from (1991-1999) showed that young individuals (20-40 years old) with CRC have a poorer overall 5 years survival compared with older individuals (60-80 year old) (61.5% vs 64.9%; P = 0.02)[8]. However, stage specific survival rates in patients with young-onset CRC equal or exceeded those with late-onset CRC[9]. In contrast to late-onset CRC, young-onset CRC has a higher incidence of recurrence and development of metastasis[10].


The pathogenesis of young-onset CRC is well characterized in individuals with an inherited CRC syndrome, in which a germline mutation in a cancer susceptibility gene is identified[11] (Table 2). Knowledge regarding the molecular features of sporadic young-onset CRC is limited[11]. Recent studies have reported that sporadic young-onset CRC may have a unique molecular profile. Sporadic young-onset CRC may be attributed to the cumulative effect of multiple genetic variants displaying variable penetrance[11]. A better understanding of these molecular mechanisms will help us tailor specific prevention and management strategies.

Table 2 Clinical and molecular features associated with hereditary colorectal cancer syndromes.
Hereditary CRC syndromeAge of presentationGene(s)Clinical features
Lynch syndromeAverage age of diagnosis of CRC is 42-45 yrMLH1, MSH2Lifetime risk of CRC 70%
MSH6,PMS2,EPCAMRisk of extracolonic cancers
Classic FAPAverage age of diagnosis of CRC is 39 yrAPC100-1000 adenomas
MUTYH (biallelic)CRC risk 90% without colectomy
Risk of extracolonic cancers
Attenuated FAPAverage age of diagnosis of CRC is 51 yrAPC, MUTYH mutations detected in approximately 10%10-99 adenomas
PJSPolyps occur during childhood and early adulthoodSTK11Mucocutaneous pigmentation
≥ 2 hamartomatous polyps in small bowel
Lifetime cancer risks 80%-90%
JPSLate childhood or early adolescenceSMAD4, BMPR1A, ENG> 3-5 juvenile polyps in the gastrointestinal tract
Congenital cardiac valvular disease and/or atrial and ventricular septal defects
PPAPSecond through fourth decades of lifePOLEOligo adenomatous polyposis
POLD1Young-onset CRC
Endometrial cancer
Cowden diseaseSecond and third decades of lifePTENVariable CRC risk
Increased risk of thyroid, breast, and endometrial cancer

The majority of young-onset cancers does not show microsatellite instability (MSI), but rather are microsatellite stable (MSS) and lack DNA repair mechanism abnormalities (Figure 1A). MSI tumors in the younger population are mostly related to Lynch Syndrome (LS) and rarely to epigenetic inactivation of MLH1[12]. Recent studies have shown that the proportion of MSI found within young-onset CRC ranges from 19.7% to 41.0% depending on the age of onset[7,13]. This relatively high proportion of MSI tumors in young CRC patients has been attributed to the high number of patients with LS in that age group. Population-based studies have found MSI in only 7% to 17% of CRC patients under age 50[14]. A study by Yiu et al[15] showed that tumors with MSI in the older age groups (60-70 years and > 87 years) were associated with MLH1 inactivation (83%) and MLH1 promoter methylation (62%), while tumors in the young group (< 45 years) were associated with MSH2 inactivation.

Figure 1
Figure 1 Molecular profile of young-onset (A) or late-onset (B) colorectal cancer.

Typically, MSS tumors have a later stage of onset, are predominately found in the right colon, and are less likely to present with synchronous and metachronous tumors[4]. Several studies have evaluated the clinicopathologic features of this subset of CRC within the young-onset population[2]. Early-onset MSS tumors are remarkably different from those in late-onset MSS CRC (Figure 1B). Left colon location, low frequency of other primary neoplasms, and an important familial component are significant features of young-onset MSS CRC[16].


Methylation of CpG islands as a mechanism of silencing genes in colon tumors has been recognized as a third pathway involved in the development of CRC. CpG island methylator phenotype (CIMP) accounts for approximately 40% of all CRCs[16]. CIMP-high tumors are associated with proximal location in the colon, poor differentiation, MSI, and BRAF mutations[2]. Compared with late-onset CRC patients, those with young-onset disease have a higher rate of CIMP-low cases. But within LS patients who have young-onset CRC, a higher proportion will be CIMP-high compared to those LS patients who develop CRC at an older age. A study by Perea et al[16], which analyzed young-onset and late-onset CRC according to the three main carcinogenic pathways, showed that young-onset CIMP-high CRCs were associated with MMR gene germline mutations. In contrast, late-onset CIMP-high CRCs were more likely to be sporadic MSI tumors. This study showed marked differences between the young-onset and late-onset CRC. Young-onset CRCs were more commonly located in the left colon, had a higher rate of CIMP-low cases and had an important family component as a result of LS-related, but also LS-unrelated, cancer history[16].


There is a subset of CRCs defined as microsatellite and chromosome stable CRC (MACS). This subset of CRCs are characterized by the absence of MSI-high and chromosomal instability (CIN). They may account for up to 30% of all sporadic CRCs[17]. They have been identified most frequently in younger cases. These tumors are most frequently located in the distal colon and rectum, have histologic features associated with poor prognosis, present with metastasis at diagnosis, and have early disease recurrence and lower survival than patients with MSI or CIN[17]. There is limited knowledge regarding the molecular profile of MACS. Recent studies have found out that MACS tumors are CIMP-low, are rarely associated with BARF mutations, have absent MLH1 expression, and seem to have a different pattern of hypomethylation when compared to MSI and CIN CRC[2]. Some published studies suggest that MACS may be related to familial CRC syndromes, based on observed increased frequency in young patients[2].


LINE-1 hypomethylation is a unique feature of young-onset CRC[18]. LINE-1 hypomethylation is a “surrogate marker for genome-wide hypomethylation” and is associated with increased CIN[12]. The degree of LINE-1 hypomethylation has been recognized as an independent factor for increased cancer related mortality and overall mortality in CRC patients[18]. A study by Antelo et al[12] whose aim was to characterize the clinical, histological, and molecular features of a large cohort of young-onset CRCs in the context of the methylation status of LINE-1, showed that compared to older-onset colorectal tumors, young-onset CRCs had significantly lower levels of LINE-1 methylation. This observation was validated in an independent set of young-onset CRC patients. These findings may help explain some of the biological mechanisms underlying young -onset CRC. Additional studies are needed to confirm this association and assess the prognostic value of LINE-1 in young-onset CRC.


Young age at onset is suggestive of a hereditary predisposition. The clinicopathological and the molecular features of young-onset CRC make it a “heterogenous disease”. There is marked heterogeneity not only when comparing young and late onset CRC, but also within the young-onset group[11]. Young-onset CRC can be further characterized into two distinct subtypes: sporadic and inherited. Individuals with young-onset sporadic CRC usually have no family history, while inherited CRC, usually arise in the context of hereditary CRC syndromes[11]. The pathogenesis of young-onset inherited CRC is well characterized. Germline mutations in known cancer-susceptibility genes have been implicated in up to 5% of all CRC[19]. Most of these hereditary syndromes have typical phenotypes, and identification of germline mutations confirm the diagnosis.


LS is the most common cause of inherited CRC and has been implicated in 2% to 4% of CRC cases[20]. It is an autosomal dominant condition defined by the presence of germline mutations in one of the mismatch repair genes MLHI, MSH2, MSH6, PMS2 or loss of expression of the MSH2 gene due to deletion in the EPCAM gene. MSI results from defective mismatch repair and is associated with loss of expression of MLHI, MSH2, MSH6, and PMS2 proteins that can be detected by immunohistochemical analysis[21]. LS is characterized by a predisposition to develop colorectal and extracolonic malignancies such as endometrial, ovarian, urinary tract, gastric, small intestine, brain, hepatobiliary, and sebaceous neoplasms[1].

Lifetime risk for developing CRC is approximately 70%[22]. Progression through the adenoma-carcinoma sequence is thought to occur in less than 5 years, compared with sporadic carcinoma, which is thought to occur over a decade[23]. A more rapid progression to carcinoma may explain their increased lifetime risk for CRC. Patients with LS also have a high rate of metachronous CRC (16% at 10 years and 41% in 20 years)[24]. Therefore, recommendations for CRC surveillance include a colonoscopy every 1 to 2 years starting at the age of 20 to 25[21].


LS is caused by a single dominant mutation in the germline. This increases the risk of cancer. LS-associated cancers develop only after a second hit occurs, which causes loss of function of the wild-type allele inherited from the unaffected parent[1]. Several genetic mechanisms are involved in the second hit including loss of heterozygosity and hypomethylation.

LS is characterized by an inactivation of one of the mismatch repair genes MLHI, MSH2, MSH6, and PMS2. Mutations in MLH1 and MSH2 account for up to 90% of cases, mutations in MSH6 account for about 10% of cases, and mutations in PMS2 account for 6% of all LS. Deletions in the 3’ end codon of the EPCAM gene can result in LS through epigenetic silencing of the MSH2 gene in tissues that express EPCAM[25]. A study by Kempers et al[26] showed that deletions in EPCAM carry a high risk of CRC.

MSI is characterized by expansion or contraction of microsatellite repeats and is found in more than 90% of CRC in patients with LS and in approximately 12% of patients with sporadic CRC[27]. MSI in CRC is due to a defect in one of the MMR genes caused by either a germline defect or a somatic change of the gene, as seen with hypermethylation of MLH1. MSI is characterized as MSI-high (≥ 30% of markers are unstable), MSH-low (< 30% of markers are unstable), and MS-stable (no markers are unstable). Most of LS tumors are MSI-high[1]. The clinical significance of MSI-low has not been defined.

Immunohistochemistry evaluates for the loss of MMR protein expression and identifies patients with LS. Alterations in specific DNA MMR are indicated by loss or partial production of the MMR protein produced by that gene. Either somatic or germline alterations in specific MMR genes are indicated by loss or partial production of the protein produced by that MMR gene[1].

Somatic mutations in the BRAF gene at codon 600 are found in approximately 15% of sporadic CRC[1]. These CRC develop through the CpG island methylator pathway and are MSI-high through somatic promoter methylation of MLH1. Somatic mutation of BRAF V600 has been detected predominantly in sporadic CRC and is usually evidence against the presence of LS[28].


Familial adenomatous polyposis (FAP) is the second most common inherited CRC syndrome and accounts for approximately 1% of the new CRC cases[19]. FAP is inherited in an autosomal dominant manner and is characterized by germline mutation in the adenomatous polyposis coli (APC) gene. Patients with classic FAP develop more than a 100 synchronous polyps beginning in the second or third decade of life. Their lifetime risk of developing CRC is estimated to exceed 99% in patients who do not undergo a colectomy[19]. Individuals with FAP are at increased risk for extracolonic cancers including: duodenal/ampullary tumors, which are the second leading cause of cancer related mortality in individuals with FAP, papillary thyroid cancer, desmoid tumors, central nervous system tumors, and adrenal tumors.

The majority of the FAP cases are caused by a germline mutation in the APC tumor suppressor gene. Most mutations in APC are nonsense or frameshift mutations that cause premature truncation of the APC protein[29]. Studies have shown an association between the location of the APC mutation and the phenotype in FAP patients[30]. The age of onset, amount of polyps, and the presence of extracolonic cancers appear to correlate with specific mutation sites[30].

Mutations located near the 5′ end of the APC gene or in the alternatively spliced region of exon 9 result in an attenuated phenotype of FAP[30]. Attenuated FAP is a milder variant of FAP, which presents with less number of colonic polyps, < 100, proximally located polyps, and an older age of presentation with CRC, compared to individuals with FAP.

MUTYH associated polyposis (MAP) is an autosomal recessive polyposis syndrome characterized by MUTYH gene mutation, most commonly Y179C and G396D. Biallelic MUTYH mutations account for 30% to 40% of cases with adenomatous polyposis in which an APC mutation cannot be detected[31]. Patients with biallelic MUTYH mutations can present with a variety of phenotypes. Some may present with colonic and extracolonic manifestations indistinguishable from FAP, but most cases present with oligopolyposis, with fewer than a 100 polyps[19]. Affected individuals have a later onset than FAP, approximately 10 years later. Biallelic carriers have an 80% cumulative lifetime risk of CRC by age 70. Some studies show that monoallelic carriers have a slightly increased risk of CRC. There appears to be a genotype-phenotype correlation with respect to cancer risk and age of onset. Individuals with homozygous Y179C mutation carriers have a more severe phenotype, with respect to age of onset and cancer risk, compared with individuals with the G396D allele[31]. A meta-analysis to assess the risk estimates associated with MUTYH variants, showed that individuals with biallelic gene mutation carriers have 28-fold increased risk, whereas those with monoallelic carries have less than 2-fold increased risk of developing CRC, when compared to the general population[32]. A study by Riegert-Johnson et al[33], which evaluated early onset CRC cases in which Lynch syndrome had been excluded by MSI testing, showed that MUTYH testing should be considered in patients with CRC diagnosed before the age of 50, found to have intact DNA MMR regardless of family history and the number of colon polyps.


Peutz-Jeghers syndrome (PJS) is an autosomal dominant hereditary CRC syndrome, which is characterized by hamartomatous polyps of the gastrointestinal tract and mucocutaneous hyperpigmented lesions. Germline mutation of the STK11/LKB1 tumor suppressor gene is known to be the underlying defect. The multiple mutations identified in STK11/LKB1 are responsible for the phenotypic variability[34]. Hamartomatous polyps are found throughout the gastrointestinal tract but most are found in the small bowel (60%-90%) and colon (50%-64%). The development of cancer in PJS polyps remains controversial. Malignant alterations have been described in hamartomas of individuals with PJS. A study by Giardiello et al[35] which evaluated 107 men and 106 women from 79 families, showed estimated cumulative cancer risks of 54% for breast, 39% for colorectal, 36% for pancreas, 29% for stomach and 21% for ovarian cancer by 64 years of age.

The only identifiable germline mutation in PJS is STK11/LKB1. It is located on chromosome 19p13.3 and acts as a tumor suppressor gene. Germline mutations of STK11/LKB1 are found in up to 70%-80% of affected families[36]. Individuals with a truncation mutation in STK11/LKB1, have an earlier age of onset than those who have a missense mutation or when no mutation is detected in STK11/LKB1[36].


Juvenile polyposis syndrome (JPS) is a hamartomatous polyposis syndrome, inherited in an autosomal dominant fashion. Unlike sporadic juvenile polyps, the polyps of individuals with JPS are more numerous and are located more proximal in the gastrointestinal tract. Individuals with JPS usually become symptomatic in childhood with symptoms of anemia, bleeding, or abdominal pain. The incidence of CRC is 17%-22% by the age of 35 and approaches 68% by the age of 60[37]. They are at increased risk for CRC and gastric cancer with a lifetime risk approaching 40%-50%[38]. This patients are also at increased risk of pancreatic and duodenal carcinomas.

Germline mutations in SMAD4 and BMPR1A have been described in patients with JPS. BMPR1A mutations are found in 40%-100% of families without SMAD4 mutation[37]. These genes encode proteins involved in transforming growth factor-beta (TGF-beta) signaling pathway[36]. SMAD4 mutations are more common and predispose to polyps in the upper digestive tract.


Germline mutations in the proofreading domains of 2 DNA polymerases, POLE and POLD1, are associated with an inherited colorectal adenoma and carcinoma syndrome, Polymerase Proofreading-Associated Polyposis (PPAP). This syndrome is inherited in an autosomal dominant manner, is highly penetrant, and is characterized by oligo adenomatous polyposis, young-onset CRC and endometrial cancer. The loss of proofreading capability causes multiple mutations throughout the genome[38]. Compared to other dominantly inherited syndromes, tumors with exonuclease domain mutations in POLE and POLD1 are MSS. Their primary mechanism or carcinogenesis is chromosomal instability, with “driver mutations” in APC and KRAS genes[39]. Germline variants in POLE and POLD1 predispose individuals to either a multiple colorectal adenoma phenotype similar to that observed in MUTYH-associated polyposis or a Lynch phenotype, in which carriers develop young-onset CRC[40]. Germline mutations in the POLE and POLD1 genes have been found to be responsible for a new form of CRC genetic predisposition[40].


Cowden syndrome is caused by germline alterations in the phosphatase and tensin homolog (PTEN) tumor suppressor gene found in chromosome 10q23. It is an autosomal dominant syndrome that is characterized by mucocutaneous lesions, hamartomatous lesions, and increased risk of breast, thyroid, and endometrial cancer[41]. Bannayan Riley Ruvalcaba syndrome is an “allelic disorder” characterized by macrocephaly, pigmented penile macules, lipomas, and hamartomatous intestinal polyps[42]. Although published case reports have shown that 35%-85% of individuals with Cowden syndrome have gastrointestinal hamartomatous polyps, there is evidence that there is significant variability in the polyp phenotype[43]. A prospective series of PTEN carriers showed variability in the polyp histology and polyp number[43]. This study determined that hamartomatous, adenomas, serrated polyps, hyperplastic polyps, and ganglioneuromas constitute the Cowden syndrome polyp histology. It is important to note that in this study, 9 individuals (13%) were diagnosed with CRC at younger than age 50[43]. This finding suggests that individuals with PTEN mutation may benefit from early CRC screening.


CRC incidence and mortality are significantly increasing in individuals younger than 50 years of age. There is significant heterogeneity in the underlying mechanisms of young-onset CRC, which have implications in the prevention, diagnosis and management of these individuals. Currently there is no evidence that supports that screening of average risk individuals less than 50 years of age, will translate into increased early detection or increased survival. However, there should be a raise in awareness of the increasing incidence of young-onset CRC. Physicians could potentially play a central role, by evaluating the risk of CRC in each patient and recommending earlier screening to those with high risk personal and family history. Further studies are warranted to increase our knowledge of the molecular mechanisms underlying young-onset CRC, and to evaluate the benefit of screening high risk individuals younger than 50 years of age. These findings will help us tailor specific prevention and management strategies.


P- Reviewer: Linnebacher M S- Editor: Ma YJ L- Editor: A E- Editor: Wang CH

1.  Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014;109:1159-1179.  [PubMed]  [DOI]
2.  Silla IO, Rueda D, Rodríguez Y, García JL, de la Cruz Vigo F, Perea J. Early-onset colorectal cancer: a separate subset of colorectal cancer. World J Gastroenterol. 2014;20:17288-17296.  [PubMed]  [DOI]
3.  Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1695-1698.  [PubMed]  [DOI]
4.  Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012;25:1128-1139.  [PubMed]  [DOI]
5.  You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med. 2012;172:287-289.  [PubMed]  [DOI]
6.  Davis DM, Marcet JE, Frattini JC, Prather AD, Mateka JJ, Nfonsam VN. Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg. 2011;213:352-361.  [PubMed]  [DOI]
7.  Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003;90:205-214.  [PubMed]  [DOI]
8.  Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J, Guiffre S, Axilbund J, Spiegel A, You YN. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216-224.  [PubMed]  [DOI]
9.  O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28:558-562.  [PubMed]  [DOI]
10.  Yeo SA, Chew MH, Koh PK, Tang CL. Young colorectal carcinoma patients do not have a poorer prognosis: a comparative review of 2,426 cases. Tech Coloproctol. 2013;17:653-661.  [PubMed]  [DOI]
11.  Stigliano V, Sanchez-Mete L, Martayan A, Anti M. Early-onset colorectal cancer: a sporadic or inherited disease? World J Gastroenterol. 2014;20:12420-12430.  [PubMed]  [DOI]
12.  Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, Cuatrecasas M, Bujanda L, Giraldez MD, Takahashi M. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One. 2012;7:e45357.  [PubMed]  [DOI]
13.  Losi L, Di Gregorio C, Pedroni M, Ponti G, Roncucci L, Scarselli A, Genuardi M, Baglioni S, Marino M, Rossi G. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol. 2005;100:2280-2287.  [PubMed]  [DOI]
14.  Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H, Eskelinen M, Härkönen N, Julkunen R, Kangas E, Ojala S. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193-2200.  [PubMed]  [DOI]
15.  Yiu R, Qiu H, Lee SH, García-Aguilar J. Mechanisms of microsatellite instability in colorectal cancer patients in different age groups. Dis Colon Rectum. 2005;48:2061-2069.  [PubMed]  [DOI]
16.  Perea J, Rueda D, Canal A, Rodríguez Y, Álvaro E, Osorio I, Alegre C, Rivera B, Martínez J, Benítez J. Age at onset should be a major criterion for subclassification of colorectal cancer. J Mol Diagn. 2014;16:116-126.  [PubMed]  [DOI]
17.  Banerjea A, Hands RE, Powar MP, Bustin SA, Dorudi S. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Dis. 2009;11:601-608.  [PubMed]  [DOI]
18.  Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734-1738.  [PubMed]  [DOI]
19.  Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12:1059-1068.  [PubMed]  [DOI]
20.  Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783-5788.  [PubMed]  [DOI]
21.  Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-62; quiz 263.  [PubMed]  [DOI]
22.  Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin JP, Järvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214-218.  [PubMed]  [DOI]
23.  Edelstein DL, Axilbund J, Baxter M, Hylind LM, Romans K, Griffin CA, Cruz-Correa M, Giardiello FM. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol. 2011;9:340-343.  [PubMed]  [DOI]
24.  Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ, Young GP, Lipton L, Winship I, Boussioutas A. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol. 2013;20:1829-1836.  [PubMed]  [DOI]
25.  Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat. 2009;30:197-203.  [PubMed]  [DOI]
26.  Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12:49-55.  [PubMed]  [DOI]
27.  Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J, Hamilton SR. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812-816.  [PubMed]  [DOI]
28.  Nakagawa H, Nagasaka T, Cullings HM, Notohara K, Hoshijima N, Young J, Lynch HT, Tanaka N, Matsubara N. Efficient molecular screening of Lynch syndrome by specific 3’ promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. Oncol Rep. 2009;21:1577-1583.  [PubMed]  [DOI]
29.  Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 1993;2:425-434.  [PubMed]  [DOI]
30.  Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007;61:153-161.  [PubMed]  [DOI]
31.  Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology. 2009;137:1883-1886.  [PubMed]  [DOI]
32.  Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, Broderick P, Gallinger S, Croitoru EM, Jenkins MA. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer. 2010;103:1875-1884.  [PubMed]  [DOI]
33.  Riegert-Johnson DL, Johnson RA, Rabe KG, Wang L, Thomas B, Baudhuin LM, Thibodeau SN, Boardman LA. The value of MUTYH testing in patients with early onset microsatellite stable colorectal cancer referred for hereditary nonpolyposis colon cancer syndrome testing. Genet Test. 2007;11:361-365.  [PubMed]  [DOI]
34.  Campos FG, Figueiredo MN, Martinez CA. Colorectal cancer risk in hamartomatous polyposis syndromes. World J Gastrointest Surg. 2015;7:25-32.  [PubMed]  [DOI]
35.  Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV, Krush AJ, Yardley JH, Luk GD. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987;316:1511-1514.  [PubMed]  [DOI]
36.  Chen HM, Fang JY. Genetics of the hamartomatous polyposis syndromes: a molecular review. Int J Colorectal Dis. 2009;24:865-874.  [PubMed]  [DOI]
37.  Schreibman IR, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol. 2005;100:476-490.  [PubMed]  [DOI]
38.  Church JM. Polymerase proofreading-associated polyposis: a new, dominantly inherited syndrome of hereditary colorectal cancer predisposition. Dis Colon Rectum. 2014;57:396-397.  [PubMed]  [DOI]
39.  Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45:136-144.  [PubMed]  [DOI]
40.  Esteban-Jurado C, Garre P, Vila M, Lozano JJ, Pristoupilova A, Beltrán S, Abulí A, Muñoz J, Balaguer F, Ocaña T. New genes emerging for colorectal cancer predisposition. World J Gastroenterol. 2014;20:1961-1971.  [PubMed]  [DOI]
41.  Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35-45.  [PubMed]  [DOI]
42.  Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet. 2011;48:505-512.  [PubMed]  [DOI]
43.  Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139:1927-1933.  [PubMed]  [DOI]